These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31935329)

  • 1. A case of platelet transfusion refractoriness due to anti-CD36 with a successful treatment outcome.
    Khatri SS; Curtis BR; Yamada C
    Immunohematology; 2019 Dec; 35(4):139-144. PubMed ID: 31935329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to random apheresis platelets versus HLA-selected platelets versus pooled platelets in HLA-sensitized patients.
    Gavva C; Barroso J; Gernsheimer T; Metcalf RA; Warner P; Pagano MB
    Transfusion; 2019 Jul; 59(7):2276-2281. PubMed ID: 31032968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal management with crossmatch-compatible platelets for refractory patients: alloimmunization, response to transfusion, and clinical outcomes (CME).
    Wiita AP; Nambiar A
    Transfusion; 2012 Oct; 52(10):2146-54. PubMed ID: 23113654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of HLA virtual cross-matched platelet transfusions for platelet transfusion refractoriness in hematopoietic stem cell transplantation.
    Seike K; Fujii N; Asano N; Ohkuma S; Hirata Y; Fujii K; Sando Y; Nakamura M; Naito K; Saeki K; Meguri Y; Asada N; Ennishi D; Nishimori H; Matsuoka KI; Tsubaki K; Otsuka F; Maeda Y
    Transfusion; 2020 Mar; 60(3):473-478. PubMed ID: 31970799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible platelet transfusions in refractory patients.
    Jia Y; Li W; Liu N; Zhang K; Gong Z; Li D; Wang L; Wang D; Jing Y; Wang J; Shan X
    Transfus Med; 2014 Dec; 24(6):406-10. PubMed ID: 25327352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA class I depletion by citric acid, and irradiation of apheresis platelets for transfusion of refractory patients.
    Mirlashari MR; Vetlesen A; Nissen-Meyer LSH; Naper C; Tjønnfjord GE; Njerve IU; Ezligini F; Landmark BF; Meinke S; Sandgren P; Höglund P; Hetland G
    Transfusion; 2021 Apr; 61(4):1222-1234. PubMed ID: 33580979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA-universal platelet transfusions prevent platelet refractoriness in a mouse model.
    Gras C; Schulze K; Goudeva L; Guzman CA; Blasczyk R; Figueiredo C
    Hum Gene Ther; 2013 Dec; 24(12):1018-28. PubMed ID: 24090417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human Leukocyte Antigen Class I Antibodies and Response to Platelet Transfusion in Patients Undergoing Liver Transplantation.
    Wong M; Narra R; Selim M; Zimmerman MA; Kim J; Padmanabhan A; Hong JC
    J Surg Res; 2020 Nov; 255():99-105. PubMed ID: 32543385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetically engineered blood pharming: generation of HLA-universal platelets derived from CD34+ progenitor cells.
    Figueiredo C; Blaszczyk R
    J Stem Cells; 2014; 9(3):149-61. PubMed ID: 25157449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteomic study of apheresis platelets made HLA class I deficient for transfusion of refractory patients.
    Mirlashari MR; Vetlesen A; Nissen-Meyer LSH; Stensland ME; Singh SK; Nyman TA; Hetland G
    Proteomics Clin Appl; 2021 Nov; 15(6):e2100022. PubMed ID: 34510746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [An evaluation of platelet transfusion response using HLA crossmatch-compatible donors in patients with platelet refractoriness].
    Hyun J; Lim YM; Park KD; Han BY; Kim YH; Han KS; Park MH
    Korean J Lab Med; 2009 Oct; 29(5):481-9. PubMed ID: 19893359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of infants born with severe neonatal alloimmune thrombocytopenia: the role of platelet transfusions and intravenous immunoglobulin.
    Bakchoul T; Bassler D; Heckmann M; Thiele T; Kiefel V; Gross I; Arnold DM; DiTomasso J; Smith JW; Paes B; Greinacher A
    Transfusion; 2014 Mar; 54(3):640-5. PubMed ID: 23869512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination
    Thuku NW; Shikuku K; Mbugua A
    Pan Afr Med J; 2017; 27():226. PubMed ID: 28979628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripartum management of HLA alloimmune platelet refractoriness.
    Peña JR; Sudhof L; O'Brien B
    Transfusion; 2018 Jul; 58(7):1583-1587. PubMed ID: 29664113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional recovery of stored platelets after transfusion.
    Bikker A; Bouman E; Sebastian S; Korporaal SJ; Urbanus RT; Fijnheer R; Boven LA; Roest M
    Transfusion; 2016 May; 56(5):1030-7. PubMed ID: 26935249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet components and gamma-irradiated platelet components.
    Sigle JP; Infanti L; Studt JD; Martinez M; Stern M; Gratwohl A; Passweg J; Tichelli A; Buser AS
    Transfusion; 2013 Aug; 53(8):1788-97. PubMed ID: 23176347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology.
    Mirasol Clinical Evaluation Study Group
    Transfusion; 2010 Nov; 50(11):2362-75. PubMed ID: 20492615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. False-negative solid-phase platelet crossmatch results due to prozone phenomenon.
    Horton RK; Zuccarelli MD; Wakefield LL; DiGuardo MA; Gandhi MJ; Juskewitch JE
    Transfusion; 2020 Dec; 60(12):3055-3059. PubMed ID: 33047855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitation of coated platelet potential during collection, storage, and transfusion of apheresis platelets.
    Charania R; Smith J; Vesely SK; Dale GL; Holter J
    Transfusion; 2011 Dec; 51(12):2690-4. PubMed ID: 21645004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the effectiveness of whole blood-derived platelets stored as a pool: a randomized block noninferiority trial.
    Heddle NM; Cook RJ; Blajchman MA; Barty RL; Sigouin CS; Boye DM; Nelson EJ; Kelton JG
    Transfusion; 2005 Jun; 45(6):896-903. PubMed ID: 15934987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.